Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy

International Journal of STD and AIDS

Volumn 11, Issue 5, 2000, Pages 336-337

  Clarke, Susan ^a   Harrington, P ^a   Condon, C ^a   Kelleher, D ^a   Smith, O P ^a   Mulcahy, F ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Antiretroviral therapy; Hepatitis; HIV; Nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DETERIORATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; TIME;

ANTI-HIV AGENTS; BIOPSY; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; NEVIRAPINE; TIME FACTORS;

EID: 0034107676     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001915831     Document Type: Article

References (5)

1. 1 Montaner JSG, Reiss P, Vella S, et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients - The INCAS Trial. JAMA 1998;279:930-7
2. 2 Havlir D, Cheesman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with HIV infection. J Infect Dis 1995;171:537-4
3. 3 Carr A, Vella S, de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996;10:635-41
4. 4 D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV infection. Ann Intern Med 1996;124:1019-30
5. 5 Skowron G, Leoung G, Dusek A, et al. Stavudine, nelfinavir, and nevirapine: preliminary safety, activity and pharmacokinetic (PK) interactions (Abstract 350). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999